1Bibliometric analysis of biomimetic drug delivery systems in China and abroadFU Li-xia, JIA Guo-shu, LIN Zhi-qiang, CUI Yi-min1521-15322Patent analysis of cinacalcet hydrochlorideJIANG Xiao-man, ZHOU Yu, YUAN Hong-mei1533-15383Clinical trial analysis of Medway——a recombinant human serum albuminWANG Yan-lin, RAO Ya-lan, YU Ai-ping, LU Shuang1539-15434Progress of clinical research on pneumococcal conjugate vaccineLIU Lin-yu, LI Ying-li1544-15505Considerations on species selection in non-clinical similarity assessment of biosimilars:an example of post-approval change of an infliximab biosimilarWANG Chen-guang, SUN Si-si, CHEN Xi-yuan1551-15566Advances in Src homology 2 domain-containing protein tyrosine phosphatase inhibitors in tumor targeting and immunotherapySHI Ge-ge, WANG Zhao-wei, QIU Yue-yuan, HE Lei, LI Zhao-zhao, SHI Jia-xin, ZHAO Bo-chen, HAN Xiao, DU Hai-chen, ZHANG Ying-qi1557-15637Research progress of nano-drug delivery system with intelligent control/response to tumor microenvironment for tumor therapyZOU Man-shu, LEI Chang, HUANG Dan, LIU Lan, HAN Yuan-shan1564-15708Advances in drug delivery of small interfering RNA therapy for Alzheimer's diseaseZHANG Yao-yao, SU Feng, CAO Jun-ru, ZHANG Jun-li, HE Guang-wei, XU Yun-gen1571-15799Construction of risk assessment index framework for clinical research in China based on Delphi methodZHANG Ai-yi, CHEN Hu, SHENG Ai-juan, BAI Nan, CHEN Yan-fen, YU Zhong-guang1580-158510(Quantitative)structure-activity relationship to assess genotoxicity of parecoxib sodium-related substancesHU Yang, NIU Jian-zhao, GUAN Hao-yue1586-159411Analysis of chemical constituents in Gymnema sylvestre(Retz.)Schult via ultra-performance liquid chromatography quadrupole time-of-flight mass spectrometryZENG Zhi-hao, XIAO Guan-lin, JIA Can-chao, JIANG Jie-yi, TANG Rui-yin, JIA De-zheng, LI Yang-xue, LI Shao-lin, BI Xiao-li1595-160712Analysis on the characteristics and influencing factors of peripheral neurotoxicity induced by antibody-drug conjugate disitamab vedotinYIN Yue, ZHANG Yan-hua1608-161413Analysis of adverse reactions in immunotherapy for 127 cases of non-small cell lung cancerLI Feng, LIANG Yan, BIAN Yuan, FANG Qiang, ZHOU Jin, ZHOU Jun-xiang, WANG Yi-xin1615-162014Data mining and analysis of security alert signals of ribociclib based on FDA adverse event reporting system databaseWU Yu-pei, YIN Yue-song, ZHANG Li-na, SUN Jie-wei1621-162715Adverse reaction analysis of mesalazine in the treatment of inflammatory bowel diseaseZHANG Meng-yuan, LIU Yi-jing, ZHU Lei1628-1632 